[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Whether Alnylam's Guidance Can Justify Analysts Finally Turning Bullish After Years of Misses

Alnylam Pharmaceuticals (ALNY) reports second-quarter fiscal 2026 earnings tomorrow, July 30, before the market opens, with analysts expecting $1.44 per share — a dramatic turnaround from the $0.52 loss posted in the same quarter last year. The central question is whether the RNAi therapeutics pioneer can sustain the momentum from its recent string of earnings beats and validate the aggressive upward revisions to full-year estimates. With the stock trading well below its 200-day moving average and technical signals flashing caution, execution against elevated expectations will be critical.

Alnylam Pharmaceuticals is a leading global biopharmaceutical company pioneering RNA interference (RNAi) therapeutics, with six approved medicines including...

Fundamentals

See More
  • Market Capitalization, $K 38,506,484
  • Shares Outstanding, K 133,513
  • Annual Sales, $ 3,714 M
  • Annual Income, $ 313,750 K
  • EBIT $ 752 M
  • EBITDA $ 808 M
  • 60-Month Beta 0.27
  • Price/Sales 10.01
  • Price/Cash Flow 99.57
  • Price/Book 34.56

Options Overview Details

View History
  • Implied Volatility 56.27% (-0.02%)
  • Historical Volatility 36.87%
  • IV Percentile 96%
  • IV Rank 89.84%
  • IV High 59.29% on 07/27/26
  • IV Low 29.56% on 08/13/25
  • Expected Move (DTE 23) 27.95 (9.75%)
  • Put/Call Vol Ratio 1.37
  • Today's Volume 3,169
  • Volume Avg (30-Day) 1,428
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 30,899
  • Open Int (30-Day) 29,854
  • Expected Range 258.67 to 314.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.44
  • Number of Estimates 8
  • High Estimate $1.86
  • Low Estimate $1.00
  • Prior Year $-0.52
  • Growth Rate Est. (year over year) +376.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
262.21 +9.31%
on 07/23/26
380.00 -24.57%
on 07/09/26
-6.90 (-2.35%)
since 06/29/26
3-Month
262.21 +9.31%
on 07/23/26
380.00 -24.57%
on 07/09/26
-14.57 (-4.84%)
since 04/29/26
52-Week
262.21 +9.31%
on 07/23/26
495.55 -42.16%
on 10/20/25
-43.93 (-13.29%)
since 07/29/25

Most Recent Stories

More News
Whether Alnylam's Guidance Can Justify Analysts Finally Turning Bullish After Years of Misses

Barchart Research What to Expect from ALNY Earnings ALNY Generated July 29, 2026 Current Price $286.62 EPS Estimate $$1.44 Consensus Rating Moderate Buy Average Move 6.38% Whether Alnylam's Guidance Can...

ALNY : 286.62 (-0.62%)
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday,...

ALNY : 286.62 (-0.62%)
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) − − Announces Completion of Enrollment in the...

ALNY : 286.62 (-0.62%)
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

AZN : 173.30 (+0.48%)
ALNY : 286.62 (-0.62%)
IONS : 54.04 (-2.28%)
BBIO : 83.54 (-2.35%)
PFE : 25.15 (-0.40%)
Strength in Chipmakers Boosts Stock Indexes

The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.27%. September E-mini S&P futures...

ALK : 45.84 (-5.70%)
SNDK : 1,015.89 (-7.32%)
FDXF : 144.36 (-4.39%)
PSKY : 7.95 (-1.49%)
STX : 764.43 (+2.29%)
WDC : 462.04 (-0.32%)
AMD : 429.56 (-5.51%)
UPS : 104.56 (-0.92%)
SPY : 729.46 (-1.54%)
MU : 739.00 (-9.94%)
ALNY : 286.62 (-0.62%)
AAL : 14.84 (-3.39%)
Stocks Climb on Strength in Chipmakers

The S&P 500 Index ($SPX ) (SPY ) today is up +0.47%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.55%. September E-mini S&P futures...

SNDK : 1,015.89 (-7.32%)
TRI : 106.34 (+2.95%)
FDXF : 144.36 (-4.39%)
PSKY : 7.95 (-1.49%)
STX : 764.43 (+2.29%)
WDC : 462.04 (-0.32%)
AMD : 429.56 (-5.51%)
UPS : 104.56 (-0.92%)
SPY : 729.46 (-1.54%)
META : 585.61 (-1.31%)
ADSK : 245.25 (+3.32%)
MU : 739.00 (-9.94%)
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10 th series of “RNAi Roundtable” webinars over...

ALNY : 286.62 (-0.62%)
Stocks Rebound on Strength in Banks and Managed Healthcare

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.41%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +1.73%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.53%. June E-mini...

PVH : 88.34 (+1.63%)
SNDK : 1,015.89 (-7.32%)
ADI : 353.37 (-3.41%)
BF.B : 29.52 (+2.15%)
ELV : 375.98 (-2.53%)
CIEN : 330.37 (-5.75%)
FIVE : 209.49 (+0.72%)
WDC : 462.04 (-0.32%)
AMD : 429.56 (-5.51%)
MDT : 87.54 (+0.76%)
SPY : 729.46 (-1.54%)
MS : 203.13 (-3.99%)
Stocks Mixed as Tech Weakness Weighs

The S&P 500 Index ($SPX ) (SPY ) today is up +0.02%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.90%. June E-mini S&P futures (ESM26...

CVS : 105.92 (-3.13%)
AVGO : 370.32 (-2.78%)
PVH : 88.34 (+1.63%)
SNDK : 1,015.89 (-7.32%)
ADI : 353.37 (-3.41%)
GLXY : 18.26 (-12.80%)
BF.B : 29.52 (+2.15%)
$IUXX : 27,192.31 (-2.06%)
COIN : 160.09 (-4.65%)
UNH : 420.57 (-1.92%)
ELV : 375.98 (-2.53%)
ZNU26 : 108-110 (-0.40%)
Weakness in Technology Stocks Pressures Stock Indexes

The S&P 500 Index ($SPX ) (SPY ) today is down -0.16%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.41%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.23%. June E-mini S&P futures (ESM26...

AMAT : 436.45 (-8.40%)
CVS : 105.92 (-3.13%)
AVGO : 370.32 (-2.78%)
PVH : 88.34 (+1.63%)
ADI : 353.37 (-3.41%)
GLXY : 18.26 (-12.80%)
BF.B : 29.52 (+2.15%)
$IUXX : 27,192.31 (-2.06%)
COIN : 160.09 (-4.65%)
UNH : 420.57 (-1.92%)
ELV : 375.98 (-2.53%)
ASML : 1,550.69 (-2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 296.55
2nd Resistance Point 293.57
1st Resistance Point 290.10
Last Price 286.62
1st Support Level 283.65
2nd Support Level 280.67
3rd Support Level 277.20

See More

52-Week High 495.55
Fibonacci 61.8% 406.41
Fibonacci 50% 378.88
Fibonacci 38.2% 351.35
Last Price 286.62
52-Week Low 262.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.